Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity.

Ozer E, Altungoz O, Unlu M, Aygun N, Tumer S, Olgun N.

Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):181-6.

PMID:
17525631
2.

Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.

Altungoz O, Aygun N, Tumer S, Ozer E, Olgun N, Sakizli M.

Cancer Genet Cytogenet. 2007 Jan 15;172(2):113-9.

PMID:
17213019
3.

Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.

Boensch M, Oberthuer A, Fischer M, Skowron M, Oestreich J, Berthold F, Spitz R.

Diagn Mol Pathol. 2005 Sep;14(3):177-82.

PMID:
16106200
4.

FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.

Spitz R, Hero B, Ernestus K, Berthold F.

Med Pediatr Oncol. 2003 Jul;41(1):30-5.

PMID:
12764740
5.

Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.

Nakagawa A, Matsuoka K, Okita H, Iwafuchi H, Hori H, Kumagai M.

Pediatr Dev Pathol. 2011 Mar-Apr;14(2):87-92. doi: 10.2350/08-12-0579.1. Epub 2011 Feb 2.

PMID:
21288077
6.
7.

No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.

Hogarty MD, Winter CL, Liu X, Guo C, White PS, Look AT, Brodeur GM, Maris JM.

Cancer Res. 2002 Nov 15;62(22):6481-4.

8.

Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R.

Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.

PMID:
26119945
9.

The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.

Tumer S, Altungoz O, Bagci O, Olgun HN.

Genet Test Mol Biomarkers. 2016 Feb;20(2):74-80. doi: 10.1089/gtmb.2015.0165. Epub 2016 Jan 20.

PMID:
26790040
10.

[Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].

Druĭ AE, Tsaur GA, Shorikov EV, Popov AM, Plekhanova OM, Typonogov SN, Savel'ev LI, Tsvirenko SV, Fechina LG.

Vopr Onkol. 2013;59(5):591-8. Russian.

PMID:
24260886
11.

Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.

Scaruffi P, Parodi S, Mazzocco K, Defferrari R, Fontana V, Bonassi S, Tonini GP.

Mol Diagn. 2004;8(2):93-100.

PMID:
15527323
12.

New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.

Simon T, Spitz R, Faldum A, Hero B, Berthold F.

J Pediatr Hematol Oncol. 2004 Dec;26(12):791-6.

PMID:
15591897
13.

High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.

Carén H, Erichsen J, Olsson L, Enerbäck C, Sjöberg RM, Abrahamsson J, Kogner P, Martinsson T.

BMC Genomics. 2008 Jul 29;9:353. doi: 10.1186/1471-2164-9-353.

14.

Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.

de Buys Roessingh AS, Rougemont AL, Wiesenauer C, Barrette S, Bouron-Dal Soglio D, Lallier M.

Eur J Pediatr Surg. 2008 Dec;18(6):410-4. doi: 10.1055/s-2008-1038923. Epub 2008 Nov 14.

PMID:
19012235
15.

High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.

Tabyaoui I, Tahiri-Jouti N, Serhier Z, El Maani K, Cherkaoui S, Al Zemmouri M, Othmani MB, Zamiati S.

Diagn Mol Pathol. 2013 Jun;22(2):112-8. doi: 10.1097/PDM.0b013e318277448e.

PMID:
23628823
16.

The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.

Souzaki R, Tajiri T, Teshiba R, Higashi M, Kinoshita Y, Tanaka S, Taguchi T.

Pediatr Surg Int. 2011 Mar;27(3):231-6. doi: 10.1007/s00383-010-2781-4.

PMID:
21046119
17.
18.

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG.

Cancer. 2016 Mar 15;122(6):935-45. doi: 10.1002/cncr.29848. Epub 2015 Dec 28.

19.
20.

Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR.

Souzaki R, Tajiri T, Higashi M, Kinoshita Y, Tanaka S, Kohashi K, Tsuneyoshi M, Taguchi T.

Pediatr Surg Int. 2008 Oct;24(10):1095-100. doi: 10.1007/s00383-008-2228-3.

PMID:
18726105

Supplemental Content

Support Center